시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 인간성장호르몬 시장 보고서(2025년)
Human Growth Hormone Global Market Report 2025
상품코드 : 1825766
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간성장호르몬 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.0%로 73억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 맞춤형 의료의 등장, 세계 헬스케어 지출 증가, 재조합 DNA 기술 도입 확대, 호르몬 대체요법에 대한 수요 증가, 내분비 질환 유병률 증가 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 신흥 시장에서의 유통망 확대, 의약품 개발에 인공지능의 통합, 지속가능한 제조 공정의 중요성, 장기 지속형 제제 개발, 유효성 향상을 위한 병용요법 활용 등이 있습니다.

향후 5년간 9.0%의 성장률 전망은 지난번 전망치보다 0.8% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과로 인해 벨기에와 프랑스에서 수입되는 유전자재조합 주사제 비용이 상승하여 미국의 의료 공급망에 혼란을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

치료 시술에 대한 인식이 높아짐에 따라 향후 인간성장호르몬 시장의 성장을 견인할 것으로 예상됩니다. 치료 절차에는 건강 상태나 질병을 완화, 관리, 치료하기 위한 의료적 개입이 포함됩니다. 이러한 인식의 증가는 의료 기술의 발전, 디지털 미디어를 통한 정보 접근성 강화, 건강과 웰빙에 대한 사람들의 관심 증가에 힘입은 바 큽니다. 인간성장호르몬(HGH) 치료는 언론의 큰 관심과 대중의 관심을 끌며 최신 의료 개입의 장점과 잠재적 응용을 강조하여 치료 절차에 대한 전반적인 인식을 높이고 있습니다. 예를 들어, 미국 약물 남용 및 정신보건관리국(SAMHSA)의 2022년 전국 약물사용 및 건강 실태조사(NSDUH) 보고서에 따르면, 2021년에는 12-17세 청소년 500만 명 중 40.6%가 지난 1년간 주요우울증(MDE)을 경험한 것으로 나타났습니다. 우울증 치료를 받고 있으며, 2022년에는 지난 1년간 MDE를 경험한 480만 명의 청소년 중 56.8%가 정신건강 치료를 받고 있습니다. 그 결과, 치료 절차에 대한 인식이 높아짐에 따라 인간성장호르몬 시장의 성장을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Human growth hormone (HGH) is a peptide hormone originating from the pituitary gland, playing a vital role in encouraging growth, cell replication, and tissue renewal across the human body. It finds application in medical interventions targeting growth hormone deficiency, promoting muscle growth, and addressing age-related issues such as muscle atrophy and decreased bone density.

The primary forms of human growth hormone are liquid and powder. Liquid human growth hormone products are typically presented as a solution or suspension, readily available for immediate consumption or injection. These include various brands such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, among others, administered via different routes such as oral, intravenous, intramuscular, or subcutaneous. These products are distributed through diverse channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, catering to a range of applications such as growth hormone (GH) deficiency, adult GH deficiency, pediatric GH deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The human growth hormone market research report is one of a series of new reports from The Business Research Company that provides human Growth hormone market statistics, including human growth hormone industry global market size, regional shares, competitors with a human growth hormone market share, detailed human growth hormone market segments, market trends, and opportunities, and any further data you may need to thrive in the human growth hormone industry. This human growth hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human growth hormone market size has grown strongly in recent years. It will grow from $4.75 billion in 2024 to $5.18 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of growth disorders, rising awareness about hormone therapies, expanding applications in sports medicine, growing geriatric population, improving healthcare infrastructure.

The human growth hormone market size is expected to see strong growth in the next few years. It will grow to $7.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to emergence of personalized medicine, rising healthcare expenditure globally, increasing adoption of recombinant DNA technology, growing demand for hormone replacement therapies, rising prevalence of endocrine disorders. Major trends in the forecast period include expansion of distribution networks in emerging markets, integration of artificial intelligence in drug development, emphasis on sustainable manufacturing processes, development of long-acting formulations, utilization of combination therapies for enhanced efficacy.

The forecast of 9.0% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for recombinant Human Growth Hormone injections imported from Belgium and France, potentially leading to higher pediatric endocrinology expenses and delayed growth disorder treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing awareness of treatment procedures is anticipated to drive the expansion of the human growth hormone market in the future. Treatment procedures encompass medical interventions aimed at alleviating, managing, or curing health conditions or diseases. This heightened awareness is fueled by advancements in medical technology, enhanced access to information via digital media, and a growing public interest in health and wellness. Human growth hormone (HGH) treatments have attracted significant media attention and public interest, underscoring the benefits and potential applications of modern medical interventions, thereby boosting overall awareness of treatment procedures. For example, according to the 2022 National Survey on Drug Use and Health (NSDUH) report by the Substance Abuse and Mental Health Services Administration (SAMHSA), among adolescents aged 12 to 17, in 2021, 40.6% of the 5.0 million adolescents with a past year Major Depressive Episode (MDE) received treatment for depression, while in 2022, 56.8% of the 4.8 million adolescents with a past year MDE received mental health treatment. Consequently, the heightened awareness of treatment procedures is propelling the growth of the human growth hormone market.

Leading companies in the human growth hormone market are intensifying their efforts in drug development and approvals to enhance their medication offerings and provide superior treatment solutions. Drug development entails a comprehensive and meticulous process involving multiple stages to ensure the safety, efficacy, and quality of a new drug before it is introduced to the market. For example, in June 2023, Pfizer Inc., a US-based biopharmaceutical company, and OPKO Health Inc., a US-based biopharmaceutical and diagnostics company, announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration (FDA). This treatment offers a more convenient dosing regimen and enhances patient adherence compared to daily injections. It provides children with growth hormone deficiency the option to reduce injection frequency from daily to once a week. The FDA approval was supported by a Phase 3 study demonstrating NGENLA's non-inferiority to once-daily somatropin, with a safety profile comparable to somatropin.

The increasing healthcare expenditure is expected to drive the growth of the human growth hormone (HGH) market in the coming years. Healthcare expenditure refers to the total spending on health services, products, and interventions aimed at improving and maintaining health. HGH therapy provides a unique approach to reducing healthcare costs by addressing underlying health issues that contribute to long-term expenses, enhancing recovery and quality of life, and potentially preventing the onset of expensive chronic conditions. For instance, in May 2023, a report from the Office for National Statistics, a UK-based government agency, indicated that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to just 0.9% in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. As a result, the rise in healthcare spending is expected to drive the human growth hormone market forward.

Major companies operating in the human growth hormone market are Pfizer Inc., Roche Holding AG, Novartis AG, Thermo Fisher Scientific Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen Pharma, Ferring Holding SA, Endo International, Zydus Lifesciences Limited, Opko Health, LG Life Sciences, EMD Serono Inc., Wockhardt Ltd., JCR Pharmaceuticals Co. Ltd., Genentech Inc., Shanghai United Imaging Healthcare Co. Ltd., SOFAR S.p.A., United Laboratories, Ascendis Pharma, Uni-Pharma S.A., Versartis Inc., Reliance Life Sciences, Anhui Anke Biotechnology (Group) Co. Ltd., Rani Therapeutics

North America was the largest region in the human growth hormone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human growth hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human growth hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The human growth hormone market consists of sales of combination therapies, sustained-release formulations, long-acting formulations, biosimilar versions, pediatric-specific formulations, and personalized dosing regimens. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Growth Hormone Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human growth hormone market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human growth hormone ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human growth hormone market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Human Growth Hormone Market Characteristics

3. Human Growth Hormone Market Trends And Strategies

4. Human Growth Hormone Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Growth Hormone Growth Analysis And Strategic Analysis Framework

6. Human Growth Hormone Market Segmentation

7. Human Growth Hormone Market Regional And Country Analysis

8. Asia-Pacific Human Growth Hormone Market

9. China Human Growth Hormone Market

10. India Human Growth Hormone Market

11. Japan Human Growth Hormone Market

12. Australia Human Growth Hormone Market

13. Indonesia Human Growth Hormone Market

14. South Korea Human Growth Hormone Market

15. Western Europe Human Growth Hormone Market

16. UK Human Growth Hormone Market

17. Germany Human Growth Hormone Market

18. France Human Growth Hormone Market

19. Italy Human Growth Hormone Market

20. Spain Human Growth Hormone Market

21. Eastern Europe Human Growth Hormone Market

22. Russia Human Growth Hormone Market

23. North America Human Growth Hormone Market

24. USA Human Growth Hormone Market

25. Canada Human Growth Hormone Market

26. South America Human Growth Hormone Market

27. Brazil Human Growth Hormone Market

28. Middle East Human Growth Hormone Market

29. Africa Human Growth Hormone Market

30. Human Growth Hormone Market Competitive Landscape And Company Profiles

31. Human Growth Hormone Market Other Major And Innovative Companies

32. Global Human Growth Hormone Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Growth Hormone Market

34. Recent Developments In The Human Growth Hormone Market

35. Human Growth Hormone Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기